Isolated antigen-binding proteins and uses thereof
Patent Information
- Application Number
- JP2024525974
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2021-10-29
- Publication Date
- 2024-11-06
- Estimated Expiration
- 2041-10-29
AI Technical Summary
Allergic diseases, including allergic rhinitis, asthma, and atopic dermatitis, are prevalent and affect a significant portion of the population, with IgE-mediated hypersensitivity reactions being a major contributor. Current treatments lack effective methods to control IgE levels and manage allergic responses.
Development of antigen-binding proteins with enhanced affinity for the neonatal FcRn receptor, providing stability and a longer half-life, which can suppress the binding of IgE to its receptors FcεRIa and FcεRII, thereby reducing allergic responses.
The antigen-binding proteins effectively inhibit IgE receptor binding, offering a potential therapeutic approach to alleviate IgE-related diseases by extending the administration cycle and improving drug discoverability and industrial production stability.
Smart Images

Figure 2024541053000002 
Figure 2024541053000003 
Figure 2024541053000004
Abstract
Citation Information
Patent Citations
Human monoclonal antibody against IgE, preparation method and purpose thereof
CN102167745A
Binding element for IgE molecule
JP2010519194A
Humanized anti-IgE antibodies that cross-link with CD23 on B lymphocytes but do not sensitize mast cells.
JP2017518320A
asct2-specific binding molecules and uses thereof
JP2018535674A
PCSK9 antibodies, antigen-binding fragments thereof and pharmaceutical uses
JP2019509254A
